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Objective
We describe the experience of our department with
positive oral food challenges (OFC) to peanut in children,
over a 10-year period.
Methods
Children who underwent a positive OFC to peanut between
November 2001 and November 2012 in the Allergy
Department of the University Hospital in Montpellier,
France, were analysed with respect to demographics,
history of atopic disease, specific IgE values, skin tests
results and the severity of both the index reaction and
the one elicited by the OFC (according to the Sampson
grades of severity)[1].
Results
69 OFC to peanut were positive in 59 (38 male and 21
female) patients, aged 3-16 years (mean age, 7.56 years).
129 OFC turned out negative over the same period of
time. All the patients were atopic. The most common
allergens were: grass mix (44.1%), cat and dog dander
(42.6%), house dust mites (38.2%), molds (29.4%) and
cypress pollen (20.5%). 24 (35.2%) patients had allergic
rhinitis and 45 (66.2%) had asthma (n=26 GINA 1, n=18
GINA 2, n=1 GINA 3). 29 (42.6% ) patients suffered
from atopic eczema. 26 patients (41%) had no history of
previous ingestion of peanuts and the avoidance regimen
had been recommended either because of positive IgE
and/or skin tests (in the context of atopic disease in early
life) or because of reactions to cross-reactive tree nuts.
32 OFC were conducted in this population, eliciting
20 grade I reactions (62.5%), 11 (34.4%) grade II reactions
and one anaphylactic shock. In the other patient group,
with a clinical history of reaction to peanut itself,
29 patients (49.2%) had a history of a grade I reaction
and 4 (6.7%) described grade II reactions. The 37 OFC
performed in these patients were followed either by
grade I or II reactions, namely the reaction was just as
severe in 21 (56.7%), more severe in 13 (35.1%) and less
severe in 3 patients (8.1%). The lowest eliciting dose,
in terms of protein content, was 25 mg.
Conclusion
OFC provides data regarding the allergic status and the
eliciting dose in patients with a suspicion of peanut
allergy. Caution is mandatory, since reactions following
OFC may be more severe than the index reaction,
despite the slow progression of doses.
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